Further, IGSF11-related peptide drugs have emerged and proved their efficacy in a variety of tumors, but there is still a need to explore and further expand the scope of tumor adaptation, and the corresponding clinical validation is lacking. This evidence concerns the gene IGSF11 and neoplasm.